Hepatitis D Infection Fact Sheet (adapted from materials developed by the Centers for Disease Control and Prevention)	
Report to Minnesota Department of Health	 Report the following to the Minnesota Department of Health: Hepatitis D infection Report to the Minnesota Department of Health by any of the following methods: Phone: 651-201-5414 or 1-877-676-5414 (toll free) Fax: 651-201-5501 Mail: Minnesota Department of Health Disease Report Card P.O. Box 64975 St. Paul, MN 55164-0975
Etiology	 Hepatitis D virus (HDV) is a defective, single-stranded RNA virus that requires the helper function of the hepatitis B virus (HBV) to replicate.
Signs and Symptoms	 HDV infection causes hepatitis only in persons with acute or chronic HBV infection; the HDV cannot produce infection in the absence of HBsAg. Symptoms are indistinguishable from HBV infection, whether HBV-HDV co-infection (simultaneously acquired) or superinfection (HDV acquired by a person with chronic HBV infection) Severe acute disease and higher risk of fulminant hepatitis with HBV-HDV co-infection The average incubation period for: Co-infection is 90 days (range 45-160 days) Superinfection is approximately 2-8 weeks.
Long-Term Effects	 Co-infection severe acute disease low risk of chronic infection Superinfection usually development of chronic HDV infection
Transmission	 High risk of severe chronic liver disease Percutaneous exposure; injecting drug use Permucosal exposure Sexual transmission is less common Perinatal transmission is rare Persons at risk for HBV infection might also be at risk for infection with hepatitis C virus (HCV) or HIV
Communicability	Persons with HBV-HDV superinfection are the primary reservoirs of infection.
Risk Groups	 Injection drug users Persons with hemophilia Infants/children of immigrants from areas with high rates of HBV infection Household contacts of chronically infected persons Persons with multiple sex partners or diagnosis of a sexually transmitted disease Men who have sex with men Sexual contacts of infected persons Infants born to infected mothers Health care and public safety workers Hemodialysis patients

Hepatitis D Infection Fact Sheet – Cont.		
Prevention	HBV-HDV co-infection:	
	Pre- or postexposure prophylaxis to prevent HBV infection	
	HBV-HDV superinfection:	
	• Education to reduce risk behaviors among persons with chronic HBV infection.	
	HBV:	
	 Hepatitis B vaccine is the best protection. Latex condoms are recommended for sexually active individuals, especially those having sex with more than one partner. The efficacy of latex condoms in preventing infection with HBV is unknown, but their proper use may reduce transmission. Pregnant women should get a blood test for HBV. Infants born to HBV-infected mothers should be given HBIG (hepatitis B immune globulin) and vaccine within 12 hours after birth. Injection drug users should be encouraged to discontinue injection drug use and to enroll in a treatment program; to never share needles, syringes, water, or "works;" and to get vaccinated against hepatitis A virus (HAV) and HBV. Individuals should not share personal care items that might be contaminated with blood (i.e. razors, toothbrushes). Patients should be encouraged to consider the risks of tattoos or body piercings. Patients who have had HBV should not donate blood, organs, or tissue. Health care or public safety workers should get vaccinated against HBV, always follow routine barrier precautions, and safely handle needles and other sharps 	
Vaccine Recommendations	 See Vaccine Recommendations section of Hepatitis B. Because HDV cannot be transmitted in the absence of HBV infection, hepatitis B immunization protects against HDV infection. Carriers of HBsAg should take extreme care to avoid exposure to HDV because no currently available immunobiologic exists for prevention of HDV superinfection. 	
Treatment & Medical Management	Supportive care	
Postexposure Management	 Carriers of HBsAg should take extreme care to avoid exposure to HDV because no currently available immunobiologic exists for the prevention of HDV superinfection. 	
Trends & Statistics	While HDV prevalence in the U.S. is low, it is most commonly found in parenteral drug users, persons with hemophilia, and persons immigrating from endemic areas.	
References	 <u>http://www.cdc.gov/ncidod/diseases/hepatitis/d/index.htm</u> (CDC website on HDV) Pickering L, eds. "Red Book 2000 Report of the Committee on Infectious Diseases, 25th ed." 2000, American Academy of Pediatrics. Atkinson W, Wolfe C, eds. "Epidemiology and Prevention of Vaccine-Preventable Diseases, 7th ed." Jan 2002, DHHS-CDC. <u>http://www.cdc.gov/nip/publications/pink/Full.htm</u> 	